Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers-Reference-Cited by-同舟云学术

Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers

Published:2019-08 Issue:8 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Magyarics Zoltan¹,Leslie Fraser²,Bartko Johann³,Rouha Harald¹,Luperchio Steven²,Schörgenhofer Christian³,Schwameis Michael⁴,Derhaschnig Ulla³,Lagler Heimo⁵,Stiebellehner Leopold⁶,Firbas Christa³,Weber Susanne¹,Campanaro Ed²,Jilma Bernd³,Nagy Eszter⁷,Stevens Chris²

Affiliation:

1. Arsanis Biosciences GmbH, Vienna, Austria

2. Arsanis, Inc., Waltham, Massachusetts USA

3. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

4. Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria

5. Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria

6. Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, Vienna, Austria

7. EveliQure Biotechnologies GmbH, Vienna, Austria

Abstract

ASN100 is a novel antibody combination of two fully human IgG1(κ) monoclonal antibodies (MAbs), ASN-1 and ASN-2, which neutralize six Staphylococcus aureus cytotoxins, alpha-hemolysin (Hla) and five bicomponent leukocidins. We assessed the safety, tolerability, and serum and lung pharmacokinetics of ASN100 in a randomized, double-blind, placebo-controlled single-dose-escalation first-in-human study.

Funder

Österreichische Forschungsförderungsgesellschaft

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00350-19

Reference28 articles.

1. Raxibacumab for the Treatment of Inhalational Anthrax

2. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review

3. Bezlotoxumab for Prevention of RecurrentClostridium difficileInfection